12 results about "Thyroid cancer cell" patented technology

The application provides GPC1 in preventing and / or treating 131 The application of inhaled internal radiation in causing thyroid cancer belongs to the technical field of biological medicine. The application takes GPC1 as 131 A treatment target of inhaled internal radiation in causing thyroid cancer, and finds that high expression of GPC1 can promote the proliferation, migration and invasion of thyroid cancer cells, and low GPC1 inhibits the occurrence and development of thyroid cancer. Therefore, the application provides application of a reagent for inhibiting, knocking down or knocking out GPC1 in preparation of a drug for preventing and / or treating thyroid cancer. The application also provides that deletion of GPC1 can effectively alleviate 131 The phenotypes of thyroid cancer caused by inhaled internal radiation, and GPC1 is an effective target for preventing and treating 131 Thyroid cancer caused by inhaled internal radiation.

The invention discloses an optical positioning method and system for papillary thyroid cancer cells of a terahertz near-field system, and relates to the field of terahertz near-field imaging, and the method comprises the following steps: carrying out the imaging observation of a thyroid tissue section under a first magnification factor through a microscope, carrying out low-magnification imaging partitioning on an area where imaging observation is located according to the morphological characteristics of the cells to form partitioned images; selecting an area of suspected papillary thyroid cancer cells, performing observation and comparison under a second magnification, comparing the observed morphology with the known optical characteristics of the papillary thyroid cancer cells, and selecting an area near the area with the suspected characteristics as an optical positioning point and performing marking; and carrying out positioning according to the optical positioning point, and carrying out scanning imaging by using a terahertz near-field system. The problems that a terahertz near-field system is long in time consumption and difficult to locate when finding papillary cancer cells in multiple cells of thyroid tissue slices are mainly solved.

This invention relates to the field of thyroid cancer drug technology, specifically to the use of acetylated honeysuckle polysaccharide in the preparation of drugs for treating thyroid cancer. This method is based on chemical structural modification of naturally derived honeysuckle polysaccharide, adjusting its molecular structure by introducing acetyl groups. The resulting acetylated honeysuckle polysaccharide exhibits relatively ideal inhibitory activity against various types of thyroid cancer cells (including differentiated and undifferentiated types). Unacetylated honeysuckle polysaccharide has almost no inhibitory effect on the more aggressive and drug-resistant undifferentiated thyroid cancer cells; after acetylation, it not only enhances the inhibitory effect on differentiated thyroid cancer cells but also demonstrates effective killing ability against undifferentiated thyroid cancer cells. This technical solution can solve the technical problem of the lack of effective treatment methods for undifferentiated thyroid cancer in the prior art and has ideal prospects for widespread application.

The application belongs to the field of biological medicine, and discloses application of an RNA helicase DHX33 inhibitor in preparation of a drug for treating or adjuvant treating thyroid cancer. The application establishes an important role of DHX33 protein in development of thyroid cancer, and provides an inhibitor having an action of inhibiting DHX33 helicase activity, thereby causing lipid peroxidation mediated by DHX33 deletion, and inducing interleukin 24 (IL-24) expression in thyroid cancer cells. The inhibitor can rapidly induce cancer cell ferroptosis, and significantly inhibit thyroid cancer cell proliferation through up-regulation of IL-24, and therefore has important medical development value.

The application provides an application of urolithin in preparation of a drug for treating thyroid cancer. Through in-vivo and in-vitro experiments, it is proved that urolithin can effectively inhibit the proliferation of thyroid cancer cells, induce the apoptosis of the thyroid cancer cells, and significantly inhibit the tumor growth in an animal model, thereby providing a new, safe and effective drug candidate for treating thyroid cancer.

The invention relates to the technical field of biological imaging, in particular to a terahertz near-field imaging recognition method for papillary thyroid cancer cells. According to the technical scheme, the method comprises the following steps: placing a thyroid cell sample in a terahertz near-field imaging system, and carrying out scanning imaging on a thyroid follicle region to obtain nanoscale resolution images of cell surface and internal structures; identifying and marking suspected cancer cells different from normal cells based on the cellular morphology and the imaging characteristics of the cell nucleus region in the image; whether the suspected cancer cells have irregular, heterotypic or amplified characteristics is judged by analyzing the cell nucleus morphology of the suspected cancer cells, and the suspected cancer cells are compared with the characteristic nucleus structure of papillary thyroid cancer, so that identification and diagnosis of single cancer cells are realized. On the basis of a terahertz near-field imaging technology, nano-scale resolution imaging can be directly carried out on cells without dyeing, cell nucleus morphological characteristics are clearly presented, and the method is easy and convenient to operate and rapid in detection.

The present invention provides CAR-T cells constructed based on the natural protein TSH. The present invention also provides chimeric antigen receptor (TAR) CAR-T cells constructed based on the tandem structure of the TSH α and β subunits, and uses thereof. The TSHαβ-CAR-T cells of the present invention can target and kill TSHR-positive thyroid cancer cells and are non-immunogenic, making them promising candidates for the treatment of thyroid cancer.

Described herein are compositions, pharmaceutical compositions, kits, and methods of use relating to anti-Dio3os antisense RNA. In embodiments, antisense Dio3os compositions, kits, and methods are described to improve symptoms of osteoporosis, for example, osteoporosis induced by a disorder characterized by a thyroid hormone imbalance (i.e., hyperthyroidism or hypothyroidism). In embodiments, antisense Dio3os compositions, kits, and methods are described to improve sensitivity of cancer cells to anti-cancer therapeutics, for example, sensitivity of ER+ breast cancer or other breast cancer cells, thyroid cancer cells, prostate cancer cells, hepatocellular cancer cells, pancreatic cancer cells, and ovarian cancer cells that are sensitized or otherwise non-responsive to cancer therapeutics (for example, aromatase inhibitors or HDAC inhibitors). Combination therapies are also contemplated utilizing antisense RNA according to the present disclosure and other drugs, for example, thyroid and anti-cancer medications.

The application provides application of VPS53 in intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the technical field of biological medicine.The application takes VPS53 as the intervention target of thyroid cancer caused by long-term low-dose ionizing radiation, finds that the copy number of VPS53 gene increases after long-term low-dose irradiation, and the expression level of VPS53 increases.In the thyroid cancer cell line with high expression of VPS53, the expression of VPS53 is knocked down, the proliferation, migration and invasion ability is weakened, the tumor volume is smaller, and the tumor grows more slowly;in the thyroid cancer cell line with low expression of VPS53, the expression of VPS53 is overexpressed, the proliferation, invasion and migration ability is enhanced, the tumor volume is larger, and the tumor grows faster.The application proves that knocking down VPS53 is a candidate intervention target of the occurrence and development of thyroid cancer caused by long-term low-dose ionizing radiation.

The present application belongs to the technical field of pharmaceutical preparation and use, and particularly relates to a composition of isofraxidin and application thereof in preparation of a medicine for treating thyroid cancer. The present application explores the role of isofraxidin in treating anaplastic thyroid cancer, and fully proves that isofraxidin can significantly inhibit the proliferation of anaplastic thyroid cancer cells, induce the apoptosis of anaplastic thyroid cancer cells, up-regulate the expression of apoptosis-related proteins cleaved-caspase3 and cleaved-PARP of anaplastic thyroid cancer cells, and inhibit the migration of anaplastic thyroid cancer cells by using a model of cell line xenograft tumor nude mice and cell in-vitro and in-vivo combination.

The present invention provides a CAR-T cell constructed on the basis of a natural protein TSH. The present invention provides a chimeric antigen receptor constructed on the basis of a TSHα subunit and TSHβ subunit tandem structure, a CAR-T cell, and a use thereof. The TSHαβ-CAR-T cell of the present invention can kill TSHR-positive thyroid cancer cells in a targeted manner, and has no immunogenicity, so that the TSHαβ-CAR-T cell has the prospect of being used in the treatment of thyroid cancer.